| Long name: |
NFkB p105/50 (13A2F) Monoclonal Antibody |
| Also known as: |
NFkB p105/50 (13A2F) Monoclonal Antibody |
| Category: |
Primary Antibodies |
| Conjugation: |
Unconjugated |
| Target Antigen: |
NFkB p105/50 |
| Specificity: |
This is a highly specific antibody against NFkB p105/50 |
| Modification(s): |
None |
| Modification site(s): |
Unmodified antibody |
| Clonality: |
Monoclonal |
| Clone number: |
13A2F |
| Concentration: |
1ug per 1ul |
| Source: |
Recombinant human protein purified from E, coli (NFkB-p50)) |
| Gene ID number: |
4790 |
| Swiss Prot: |
P19838 |
| Tested Applications: |
WB |
| Recommended dilutions: |
5 ug/ml), WB (0 |
| Cross reactivity: |
Mouse, Rat, Human |
| Cross reactive species details: |
not every possible cross-reactivity is known, Due to limited amount of testing and knowledge |
| Background of the target antigen: |
Different dimer combinations act as transcriptional activators or repressors, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, In a conventional activation pathway, NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family, NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators, NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors, NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one, RELB, The NF-kappa-B p50-p50 homodimer is a transcriptional repressor, The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity, but can act as a transcriptional activator when associated with BCL3, cell growth, differentiation, immunity, respectively, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus, tumorigenesis and apoptosis, NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation |
| Purification method: |
Purified by Protein G |
| Storage conditions: |
50% glycerol and 0, Store at -20°, 09% sodium azide, C for up to 1 year, Keep the antibody in aqueous buffered solution containing 1% BSA |
| Synonym names: |
CVID12, DNA-binding factor KBF1, EBP-1, KBF1, NF-kB1, NF-kappa-B, NF-kappaB, NFKB-p105, NFKB-p50, NFKB1, NFkappaB, Nuclear factor NF-kappa-B p105 subunit, Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1, p105, p50 |
| Properties: |
C, C for long term storage and for short term at + 5°, If you buy Antibodies supplied by Bioss Primary Unconjugated Antibodies they should be stored frozen at - 24° |
| About: |
Each murine monoclonal anibody has his own affinity specific for the clone, Mouse monoclonal antibodies are purified protein A or G and can be conjugated to FITC for flow cytometry or FACS and can be of different isotypes, Monoclonals of this antigen are available in different clones |
| Gene target: |
NFkB p105/50 (13A2F) Monoclonal |
| Short name: |
NFkB p105/50 (13A2F) Monoclonal Antibody |
| Technique: |
Monoclonals or monoclonal antibodies, antibodies against human proteins, antibodies for, Antibody |
| Alternative name: |
NFkB p105/50 (13A2F) monoclonal (Antibody to) |
| Alternative technique: |
antibodies |